{"ticker": {"uuid": "9e320e7d-57a2-4e01-8792-f189ab2aeef9", "symbol": "CNTX", "name": "Context Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Enterprise value to revenue forward of Context Therapeutics, Inc. \u2013 DUS:6K9", "summary": "This article provides financial information for Context Therapeutics, Inc. (DUS:6K9), specifically focusing on its enterprise value to revenue forward metric. The content highlights the company's financial data available on TradingView, along with standard disclaimers about marke", "url": "https://www.tradingview.com/symbols/DUS-6K9/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-16T03:39:46", "published_display": "16 Jul 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxQSW9mM3I5d1lnaHgzVDlPNFgzSVg3MFNNVmk0N0hLcGh3dko0MF9kWUVzS1phTmdDU1NjUGFZamZZWTBmdnFfanllME9NWmhxd0JiMjJzM3JCQU9SVnY0cEx3T3JnT1pDUlh3Vy0xR1lDem9hZ2ZqdUFXd2UzU1JRbkczUEdHZ1hSRGdTN1JfSHgtLUxQVTBJRjNGbS15Z05pZVd0a25wZl9OX0VjNnp4WHVVOUxxeUVwbTJ1TmdMTzZvcEZVbTkzSDdEUFhvZTdtZC1fb3R2SFZ4ZzQ?oc=5", "source_name": "StockStory", "published_at": "2026-07-15T07:00:00+00:00", "published_display": "15 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Enterprise value to EBITDA forward of Context Therapeutics, Inc. \u2013 DUS:6K9", "summary": "This article provides financial information for Context Therapeutics, Inc. (DUS:6K9), focusing on its enterprise value to EBITDA forward. It includes a table displaying the period, value, and percentage change for this metric, noting that the data was \"Made by humans.\" The page a", "url": "https://www.tradingview.com/symbols/DUS-6K9/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-15T03:11:44", "published_display": "15 Jul 2026 03:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics (CNTX) Leerink Global Healthcare Conference 2026 Summary", "summary": "Context Therapeutics (CNTX) presented key strategic and pipeline priorities at the Leerink Global Healthcare Conference 2026, focusing on T-cell engagers for solid tumors, particularly to address ADC resistance. Their Claudin 6 program is targeting platinum-resistant, ADC-exposed", "url": "https://quartr.com/events/context-therapeutics-cntx-leerink-global-healthcare-conference-2026_Fe3mpBh5", "source_name": "Quartr", "published_at": "2026-07-11T15:11:40", "published_display": "11 Jul 2026 15:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Context Therapeutics Inc. (Nasdaq: CNTX) announced an inducement grant of a non-qualified stock option award to a new employee for 146,000 shares of common stock. This grant was made outside the company's 2021 Long-Term Performance Incentive Plan, as permitted by Nasdaq Listing R", "url": "https://www.globenewswire.com/news-release/2026/07/10/3325745/0/en/context-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4.html", "source_name": "GlobeNewswire", "published_at": "2026-07-11T14:10:46", "published_display": "11 Jul 2026 14:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics (CNTX) Proxy filing Summary", "summary": "Context Therapeutics (CNTX) has released a summary of its proxy filing for the 2026 Annual Meeting, scheduled virtually for June 24, 2026. Shareholders will vote on director elections, auditor ratification, and a significant increase in authorized common stock from 200 million to", "url": "https://quartr.com/events/context-therapeutics-cntx-proxy-filing_Fe3mpfae", "source_name": "Quartr", "published_at": "2026-07-11T09:40:49", "published_display": "11 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Context Therapeutics hire receives 146,000-share stock option at $0.70", "summary": "Context Therapeutics (Nasdaq: CNTX) granted a new employee a non-qualified stock option to purchase 146,000 shares of common stock at an exercise price of $0.70 per share. This inducement award was granted under Nasdaq Listing Rule 5635(c)(4) and falls outside the company's 2021 ", "url": "https://www.stocktitan.net/news/CNTX/context-therapeutics-announces-inducement-grant-under-nasdaq-listing-al5e456vux47.html", "source_name": "Stock Titan", "published_at": "2026-07-10T19:39:47", "published_display": "10 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics Inc (CNTX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMib0FVX3lxTE82d1lUcUE5NGZwRVVsUWN5RW11Z1dwVWVyZ25teUlzNUxpNU11RGVmam9kT2hGUDh0UGtYeTBQOFlwLVZJS1dJd2NkS0YwbFlta0JtTmF3c2o2WnBYOXZ1ZHQxWEF1bHpDMUtEVzg2aw?oc=5", "source_name": "TradingKey", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics Added to Russell 2000 and Russell 3000 Indexes", "summary": "Context Therapeutics Inc. (Nasdaq: CNTX), a clinical-stage biopharmaceutical company, announced its inclusion in the small-cap Russell 2000 and broad-market Russell 3000 Indexes, effective June 26, 2026. This inclusion is significant as these indexes are widely used benchmarks by", "url": "https://www.marketscreener.com/news/context-therapeutics-added-to-russell-2000-and-russell-3000-indexes-ce7f5ed8d88cf024", "source_name": "www.marketscreener.com", "published_at": "2026-07-07T09:11:00", "published_display": "07 Jul 2026 09:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics Joins Russell 2000, Russell 3000 Indexes", "summary": "Context Therapeutics (Nasdaq: CNTX) has announced its inclusion in the Russell 2000 and Russell 3000 Indexes, effective after the U.S. markets opened on June 28, 2024. This inclusion positions the company among the largest U.S. stocks, boosting its visibility and potentially attr", "url": "https://www.moomoo.com/news/post/72539064/context-therapeutics-joins-russell-2000-russell-3000-indexes", "source_name": "Moomoo", "published_at": "2026-07-07T01:12:30", "published_display": "07 Jul 2026 01:12", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics Added to Russell 2000\u00ae and Russell 3000\u00ae Indexes", "summary": "Context Therapeutics Inc. (Nasdaq: CNTX), a clinical-stage biopharmaceutical company, announced its inclusion in the small-cap Russell 2000\u00ae and the broad-market Russell 3000\u00ae Indexes. This move was effective at the close of U.S. equity markets on June 26, 2026. These indexes are", "url": "https://www.globenewswire.com/news-release/2026/07/06/3322747/0/en/context-therapeutics-added-to-russell-2000-and-russell-3000-indexes.html", "source_name": "GlobeNewswire", "published_at": "2026-07-07T01:12:29", "published_display": "07 Jul 2026 01:12", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics stock rises on Russell index inclusion By Investing.com", "summary": "Context Therapeutics Inc. (NASDAQ:CNTX) shares rose by 2.7% in after-hours trading following its inclusion in the Russell 2000 and Russell 3000 indexes on June 26, 2026. This inclusion is expected to increase institutional ownership as index funds adjust their portfolios. The com", "url": "https://ng.investing.com/news/stock-market-news/context-therapeutics-stock-rises-on-russell-index-inclusion-93CH-2587608", "source_name": "Investing.com Nigeria", "published_at": "2026-07-06T20:40:20", "published_display": "06 Jul 2026 20:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics joins Russell 2000 and 3000 indexes", "summary": "Context Therapeutics (Nasdaq: CNTX), a clinical-stage biopharmaceutical company, announced its inclusion in the small-cap Russell 2000\u00ae and the broad-market Russell 3000\u00ae Indexes. This addition, effective June 26, 2026, aligns CNTX with major U.S. equity benchmarks, potentially b", "url": "https://www.stocktitan.net/news/CNTX/context-therapeutics-added-to-russell-2000-and-russell-3000-pr5u58hmraw4.html", "source_name": "Stock Titan", "published_at": "2026-07-06T19:40:20", "published_display": "06 Jul 2026 19:40", "sentiment": "positive", "sentiment_pct": 88, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics stock rises on Russell index inclusion", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNU0ZvYlZrQ1FCTWlrcmdNNmg1ZDN5X2dGOV9WUmRjY3ZVQ3AzQXlvcllqcm1tbnBDZDFUd0lCNnczcklWUnlYOWZ5QnVEYk5TaVh6XzV6Si1ZVUtqWEJRMU1oaXJTNVVpam5IcXgyMzdoSG9ZU1NoUEtXdDhfMWdvQ3dsXzZfYXkycG1EZkNCa0s5WC1VX2VQc3h2X2dxbzBvSmRBTGVwaS1iZVFEbTE5OEZQbU1EWkg1eHAzVWFR?oc=5", "source_name": "Investing.com", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Diluted net income available to common stockholders of Context Therapeutics, Inc. \u2013 DUS:6K9", "summary": "This article displays the \"Diluted net income available to common stockholders\" for Context Therapeutics, Inc. (DUS:6K9) on the TradingView platform. It provides a placeholder for the period, value, and change in this financial metric, indicating that the data itself would be pre", "url": "https://www.tradingview.com/symbols/DUS-6K9/financials-income-statement/diluted-net-income/", "source_name": "TradingView", "published_at": "2026-07-06T05:41:20", "published_display": "06 Jul 2026 05:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maxim Says Context Therapeutics (CNTX)\u2019s Share Pullback Is an Overreaction; Remains Bullish", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOQkhFazJGSkI0Rm5wbmduVE5OOUtWSjM0bVktakFmM3lYZTJzRTh0MkZrVFF6b0pqcktxd1ZkRFZTQW1aMDJoMUtRWS1MN2p5T0xrQXJUbGozWGxaZzBjV2x5RVZSZnc0djZna0RQeFNrN1oyeWlwVHo5c28wUTdScVBEUzltS1lpUjNfcEpGbGx2Sm1Xdklyb1owQTg3dHBYU2tR?oc=5", "source_name": "Market source", "published_at": "2026-07-05T07:00:00+00:00", "published_display": "05 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics Inc.(NasdaqCM:CNTX) added to Russell Microcap Growth Benchmark Index", "summary": "Context Therapeutics Inc. (NasdaqCM:CNTX) has been added to the Russell Microcap Growth Benchmark Index. This inclusion is part of several recent additions to various Russell indices, highlighting increased visibility for the biopharmaceutical company. Context Therapeutics focuse", "url": "https://www.marketscreener.com/news/context-therapeutics-inc-nasdaqcm-cntx-added-to-russell-microcap-growth-benchmark-index-ce7f5fded088f621", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T12:41:40", "published_display": "29 Jun 2026 12:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics Inc.(NasdaqCM: CNTX) added to Russell 3000E Growth Benchmark", "summary": "Context Therapeutics Inc. (NasdaqCM: CNTX) has been included in the Russell 3000E Growth Benchmark. This addition reflects the company's growth trajectory within the biotechnology and medical research sector. The article also provides a company profile, recent news, and various f", "url": "https://www.marketscreener.com/news/context-therapeutics-inc-nasdaqcm-cntx-added-to-russell-3000e-growth-benchmark-ce7f5fdedf88f320", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T08:40:20", "published_display": "29 Jun 2026 08:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Context Therapeutics, Inc. \u2013 MUN:6K9", "summary": "The article presents the \"Enterprise value to EBITDA forward\" metric for Context Therapeutics, Inc. (MUN:6K9) on the Munich Stock Exchange. It indicates that the market was closed with no trades recorded at the time of publication. The data is provided by FactSet Research Systems", "url": "https://www.tradingview.com/symbols/MUN-6K9/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T01:40:20", "published_display": "29 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Context Therapeutics Inc. \u2013 NASDAQ:CNTX", "summary": "This article provides financial data for Context Therapeutics Inc. (NASDAQ: CNTX), specifically focusing on its forward price-to-earnings ratio. It indicates that the company's financial information is available through TradingView, utilizing market data from ICE Data Services an", "url": "https://www.tradingview.com/symbols/NASDAQ-CNTX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T14:10:46", "published_display": "28 Jun 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Context Therapeutics Inc. \u2013 NASDAQ:CNTX", "summary": "This article provides financial data for Context Therapeutics Inc. (NASDAQ: CNTX), specifically focusing on its Price to Book Forward value. The content is presented within the TradingView platform, offering various financial tools and market data services.", "url": "https://www.tradingview.com/symbols/NASDAQ-CNTX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T20:10:21", "published_display": "27 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics (NASDAQ: CNTX) wins approval to lift share authorization to 300M", "summary": "Context Therapeutics (NASDAQ: CNTX) announced that its stockholders approved an amendment to increase the authorized common shares from 200 million to 300 million at their annual meeting on June 24, 2026. This decision provides the company with greater flexibility for future equi", "url": "https://www.stocktitan.net/sec-filings/CNTX/8-k-context-therapeutics-inc-reports-material-event-0e78f63100b2.html", "source_name": "Stock Titan", "published_at": "2026-06-26T21:09:42", "published_display": "26 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Context Therapeutics (CNTX) receives 45,000 stock options award", "summary": "Context Therapeutics Inc. (CNTX) director Karen L. Smith was granted 45,000 stock options with an exercise price of $0.576 per share, expiring on June 23, 2036. The options will vest on the earlier of June 24, 2027, or the company\u2019s 2027 annual meeting, contingent on her continue", "url": "https://www.stocktitan.net/sec-filings/CNTX/form-4-context-therapeutics-inc-insider-trading-activity-a47ea5ef3244.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:11:10", "published_display": "26 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics (CNTX) director awarded 45,000 stock options at $0.576", "summary": "Context Therapeutics Inc. director Stacey Jennifer Evans was granted 45,000 stock options at an exercise price of $0.576 per share. This compensation-related grant will vest on the earlier of June 24, 2027, or the company\u2019s 2027 annual meeting, contingent on her continued service", "url": "https://www.stocktitan.net/sec-filings/CNTX/form-4-context-therapeutics-inc-insider-trading-activity-46bdb4d41fda.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:11:10", "published_display": "26 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics (CNTX) director Linda West awarded 45K stock options", "summary": "Context Therapeutics director Linda West was granted 45,000 stock options to acquire common stock at an exercise price of $0.576 per share, expiring on June 23, 2036. The options will vest on the earlier of June 24, 2027, or the company\u2019s 2027 annual meeting, contingent on her co", "url": "https://www.stocktitan.net/sec-filings/CNTX/form-4-context-therapeutics-inc-insider-trading-activity-fd607db4f2e9.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:11:10", "published_display": "26 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics (CNTX) director receives grant of 45,000 stock options at $0.576", "summary": "Context Therapeutics Inc. director Andy Pasternak was granted 45,000 stock options with an exercise price of $0.576 per share, expiring on June 23, 2036. The options will vest on the earlier of June 24, 2027, or the company's 2027 annual meeting, dependent on his continued servic", "url": "https://www.stocktitan.net/sec-filings/CNTX/form-4-context-therapeutics-inc-insider-trading-activity-3a32fab9a01b.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:11:10", "published_display": "26 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics, Inc. Actuals & Estimates (NASDAQ:CNTX)", "summary": "This article provides an in-depth financial overview of Context Therapeutics Inc. (NASDAQ: CNTX), including its current stock price, historical performance, analyst forecasts, and key financial metrics like market capitalization and upcoming earnings reports. It also answers freq", "url": "https://www.tradingview.com/symbols/NASDAQ-CNTX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T07:10:15", "published_display": "26 Jun 2026 07:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics Highlights Positive CTIM-76 Phase 1 Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxOTk1lbFZidUx4bVVkYmdMZm1qMEtwb21pYVRhVV9VcE12eUNJZG5abjlYSGhyMGN1LWk1RVFKLS1JMXFqNnR5NHdLbkhBY0xoNHJoaFlzWWtzdTIwYmhJNVQ2VDhZcWs4Smc0amJxTlplRFFPVlp3YWxsLWIzWGhNMDNIQnJJMDV1WnlFZm1pNkc2OHNDVW9qMzJlaEJ5ZW05S0R3SXpVaWFiTFNVZWlkS1BKR19hRmVCdUhJNmZoMzJ0aFVoTFJsVlpEN3V1VHA5bnVxS2NWc1pEV3FrT0g4?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Study", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/small-biotech-context-therapeutics-reports-151023916.html", "source_name": "Benzinga", "published_at": "2026-06-15T15:10:23+00:00", "published_display": "15 Jun 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics to Proceed With Next Development Phase of CTIM-76 in Ovarian Cancer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/context-therapeutics-proceed-next-development-111656279.html", "source_name": "MT Newswires", "published_at": "2026-06-15T11:16:56+00:00", "published_display": "15 Jun 2026 11:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/context-therapeutics-announces-positive-interim-103000152.html", "source_name": "GlobeNewswire", "published_at": "2026-06-15T10:30:00+00:00", "published_display": "15 Jun 2026 10:30", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics Announces Positive Interim Efficacy", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAJBVV95cUxPalBnUWowcERlc1hFR2xKQ1NJc1RhN1VxMXBLa1plUVVpYzBEejVXZ3FTWmNEMWh4a1VkTHphaVhobE9UdnpnSWVfMV9VM2Q4N1IxaGZwZVVHSGZLTmJyMTdqbTl2cUltQUJWNEFTTW4zY3dCcmgzZWFnSF9xLWFreHMzd05PX3pEUDQxRUNvd3Y1LVdNdHVvTDBsdGVmQW9NSjRmNkp4akFrNGNmV2RKbTFYd0hta2pZYWVzZnVpb2pQYUQ2am5GV29TUzVwWlc0T0pfVER5d2NEaDRhVVY2czZiVTNrOGU0ejZ4a2lFSnlHMjQzdUlLclNwYU12QVE5bFJWSTNfV2x4WGdpdTdfUnJucVFqamozamlTSnptTjc?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics (NASDAQ: CNTX) shows early CTIM-76 activity in platinum-resistant ovarian cancer", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPejhseEJQdjZLbkRheWxOTHp3b3c3TDB5OXUzUDljN1g2VnZDdDU5ellYUTdOU3JyUDM5b0ExZ0N3OXlWdDVaTXQyLUIxZDJYNnJnaDAweHJ3b3FoTWFOSXBlbmE1M3ZXcFppS3puR0dwTVFtd1J3QjBRT05QbEVHdUZ4aDR4UTRFZEszaldBN0hfaVJBUlRnNktvTVpGS0FKT0lXRkFkVE1QY0N6cFk1QmhVNA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics to Present at the Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/context-therapeutics-present-jefferies-global-113000392.html", "source_name": "GlobeNewswire", "published_at": "2026-05-27T11:30:00+00:00", "published_display": "27 May 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics Decline Means Insider Profits Down To US$237k", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics Secures Full Rights to CT-202 Under Revised BioAtla Deal", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/context-therapeutics-secures-full-rights-112945130.html", "source_name": "MT Newswires", "published_at": "2026-05-18T11:29:45+00:00", "published_display": "18 May 2026 11:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Positive Signs As Multiple Insiders Buy Context Therapeutics Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQTmlUcjlidjRLZk5KeXEzNmNQNktrLVZPQUlQa2ZJUWpsUDhmZGNXZ0d4elVKX1BfSU9hN0lHbVliLXhrdmNLQlpzV1o5VVQyRVpEZDc3REgyQ184WUpjVGxKQkZtUjZ1X19uRzVXWmRsNGp1RVVILXJKMmNPZnNucV9mNy16VWd3bV80VHlwNUc1LVM4dHdnMW03RW5JbnFJdlBF?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Here's Why We're Not Too Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTFB4a3IxaEZYQTVoc3pYbFlNV2gyd19tMU40QXhsSGl3cHhWVnZ6bWlrQlFWcjFyN1VJZW1YWndqd1loYlo5X3BpUXl0OTcwWEVSRDhoQjBwNlBpYl82bE1CXzR6UTVHWWFaNkdPUS1RVC01UG9iTkhB?oc=5", "source_name": "Market source", "published_at": "2026-02-05T08:00:00+00:00", "published_display": "05 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Hopeful That Context Therapeutics (NASDAQ:CNTX) Will Use Its Cash Wisely", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-19T08:00:00+00:00", "published_display": "19 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics (CNTX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5jNFdtMlFGaXhLcURsZmNsU3NfWlEwX2VfUnN5aFg3X2JKb3c5OHJmcEdHYm5GNzlubXpPV0hHdVM5eE1IRHY3Y3d0TG5JVW5NcFg0djNTbTItUQ?oc=5", "source_name": "MarketBeat", "published_at": "2021-10-25T23:22:47+00:00", "published_display": "25 Oct 2021 23:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics Completes $25M IPO", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPTVlpa1k4Qy16OXVuWEVNMzc1ckkxOUo5dzNJNmJtQUVIeDBvWVJtaTRYSmktVlJyeVAxVVlUZUQwM1JtQ0swUUxJcm5ubE9CWnI3NGE0SzVxVUF1UUlhZGtZaUY2ZmJZczdKQmczM0NQWjZJOHpOOFBLbHUweUZ4MFdiUkNKNUFPbGtQRGZaUjAtZXdycG5wOE1PLUpSMkdRbkE?oc=5", "source_name": "Faegre Drinker Biddle & Reath LLP", "published_at": "2021-10-19T07:00:00+00:00", "published_display": "19 Oct 2021 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Enterprise value to revenue forward of Context Therapeutics, Inc. \u2013 DUS:6K9", "summary": "This article provides financial information for Context Therapeutics, Inc. (DUS:6K9), specifically focusing on its enterprise value to revenue forward metric. The content highlights the company's financial data available on TradingView, along with standard disclaimers about marke", "url": "https://www.tradingview.com/symbols/DUS-6K9/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-16T03:39:46", "published_display": "16 Jul 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Context Therapeutics, Inc. \u2013 DUS:6K9", "summary": "This article provides financial information for Context Therapeutics, Inc. (DUS:6K9), focusing on its enterprise value to EBITDA forward. It includes a table displaying the period, value, and percentage change for this metric, noting that the data was \"Made by humans.\" The page a", "url": "https://www.tradingview.com/symbols/DUS-6K9/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-15T03:11:44", "published_display": "15 Jul 2026 03:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics (CNTX) Leerink Global Healthcare Conference 2026 Summary", "summary": "Context Therapeutics (CNTX) presented key strategic and pipeline priorities at the Leerink Global Healthcare Conference 2026, focusing on T-cell engagers for solid tumors, particularly to address ADC resistance. Their Claudin 6 program is targeting platinum-resistant, ADC-exposed", "url": "https://quartr.com/events/context-therapeutics-cntx-leerink-global-healthcare-conference-2026_Fe3mpBh5", "source_name": "Quartr", "published_at": "2026-07-11T15:11:40", "published_display": "11 Jul 2026 15:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Context Therapeutics Inc. (Nasdaq: CNTX) announced an inducement grant of a non-qualified stock option award to a new employee for 146,000 shares of common stock. This grant was made outside the company's 2021 Long-Term Performance Incentive Plan, as permitted by Nasdaq Listing R", "url": "https://www.globenewswire.com/news-release/2026/07/10/3325745/0/en/context-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4.html", "source_name": "GlobeNewswire", "published_at": "2026-07-11T14:10:46", "published_display": "11 Jul 2026 14:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics (CNTX) Proxy filing Summary", "summary": "Context Therapeutics (CNTX) has released a summary of its proxy filing for the 2026 Annual Meeting, scheduled virtually for June 24, 2026. Shareholders will vote on director elections, auditor ratification, and a significant increase in authorized common stock from 200 million to", "url": "https://quartr.com/events/context-therapeutics-cntx-proxy-filing_Fe3mpfae", "source_name": "Quartr", "published_at": "2026-07-11T09:40:49", "published_display": "11 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Context Therapeutics hire receives 146,000-share stock option at $0.70", "summary": "Context Therapeutics (Nasdaq: CNTX) granted a new employee a non-qualified stock option to purchase 146,000 shares of common stock at an exercise price of $0.70 per share. This inducement award was granted under Nasdaq Listing Rule 5635(c)(4) and falls outside the company's 2021 ", "url": "https://www.stocktitan.net/news/CNTX/context-therapeutics-announces-inducement-grant-under-nasdaq-listing-al5e456vux47.html", "source_name": "Stock Titan", "published_at": "2026-07-10T19:39:47", "published_display": "10 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics Inc (CNTX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMib0FVX3lxTE82d1lUcUE5NGZwRVVsUWN5RW11Z1dwVWVyZ25teUlzNUxpNU11RGVmam9kT2hGUDh0UGtYeTBQOFlwLVZJS1dJd2NkS0YwbFlta0JtTmF3c2o2WnBYOXZ1ZHQxWEF1bHpDMUtEVzg2aw?oc=5", "source_name": "TradingKey", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics Added to Russell 2000 and Russell 3000 Indexes", "summary": "Context Therapeutics Inc. (Nasdaq: CNTX), a clinical-stage biopharmaceutical company, announced its inclusion in the small-cap Russell 2000 and broad-market Russell 3000 Indexes, effective June 26, 2026. This inclusion is significant as these indexes are widely used benchmarks by", "url": "https://www.marketscreener.com/news/context-therapeutics-added-to-russell-2000-and-russell-3000-indexes-ce7f5ed8d88cf024", "source_name": "www.marketscreener.com", "published_at": "2026-07-07T09:11:00", "published_display": "07 Jul 2026 09:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics Joins Russell 2000, Russell 3000 Indexes", "summary": "Context Therapeutics (Nasdaq: CNTX) has announced its inclusion in the Russell 2000 and Russell 3000 Indexes, effective after the U.S. markets opened on June 28, 2024. This inclusion positions the company among the largest U.S. stocks, boosting its visibility and potentially attr", "url": "https://www.moomoo.com/news/post/72539064/context-therapeutics-joins-russell-2000-russell-3000-indexes", "source_name": "Moomoo", "published_at": "2026-07-07T01:12:30", "published_display": "07 Jul 2026 01:12", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics Added to Russell 2000\u00ae and Russell 3000\u00ae Indexes", "summary": "Context Therapeutics Inc. (Nasdaq: CNTX), a clinical-stage biopharmaceutical company, announced its inclusion in the small-cap Russell 2000\u00ae and the broad-market Russell 3000\u00ae Indexes. This move was effective at the close of U.S. equity markets on June 26, 2026. These indexes are", "url": "https://www.globenewswire.com/news-release/2026/07/06/3322747/0/en/context-therapeutics-added-to-russell-2000-and-russell-3000-indexes.html", "source_name": "GlobeNewswire", "published_at": "2026-07-07T01:12:29", "published_display": "07 Jul 2026 01:12", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics stock rises on Russell index inclusion By Investing.com", "summary": "Context Therapeutics Inc. (NASDAQ:CNTX) shares rose by 2.7% in after-hours trading following its inclusion in the Russell 2000 and Russell 3000 indexes on June 26, 2026. This inclusion is expected to increase institutional ownership as index funds adjust their portfolios. The com", "url": "https://ng.investing.com/news/stock-market-news/context-therapeutics-stock-rises-on-russell-index-inclusion-93CH-2587608", "source_name": "Investing.com Nigeria", "published_at": "2026-07-06T20:40:20", "published_display": "06 Jul 2026 20:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics joins Russell 2000 and 3000 indexes", "summary": "Context Therapeutics (Nasdaq: CNTX), a clinical-stage biopharmaceutical company, announced its inclusion in the small-cap Russell 2000\u00ae and the broad-market Russell 3000\u00ae Indexes. This addition, effective June 26, 2026, aligns CNTX with major U.S. equity benchmarks, potentially b", "url": "https://www.stocktitan.net/news/CNTX/context-therapeutics-added-to-russell-2000-and-russell-3000-pr5u58hmraw4.html", "source_name": "Stock Titan", "published_at": "2026-07-06T19:40:20", "published_display": "06 Jul 2026 19:40", "sentiment": "positive", "sentiment_pct": 88, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics stock rises on Russell index inclusion", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNU0ZvYlZrQ1FCTWlrcmdNNmg1ZDN5X2dGOV9WUmRjY3ZVQ3AzQXlvcllqcm1tbnBDZDFUd0lCNnczcklWUnlYOWZ5QnVEYk5TaVh6XzV6Si1ZVUtqWEJRMU1oaXJTNVVpam5IcXgyMzdoSG9ZU1NoUEtXdDhfMWdvQ3dsXzZfYXkycG1EZkNCa0s5WC1VX2VQc3h2X2dxbzBvSmRBTGVwaS1iZVFEbTE5OEZQbU1EWkg1eHAzVWFR?oc=5", "source_name": "Investing.com", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Diluted net income available to common stockholders of Context Therapeutics, Inc. \u2013 DUS:6K9", "summary": "This article displays the \"Diluted net income available to common stockholders\" for Context Therapeutics, Inc. (DUS:6K9) on the TradingView platform. It provides a placeholder for the period, value, and change in this financial metric, indicating that the data itself would be pre", "url": "https://www.tradingview.com/symbols/DUS-6K9/financials-income-statement/diluted-net-income/", "source_name": "TradingView", "published_at": "2026-07-06T05:41:20", "published_display": "06 Jul 2026 05:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maxim Says Context Therapeutics (CNTX)\u2019s Share Pullback Is an Overreaction; Remains Bullish", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOQkhFazJGSkI0Rm5wbmduVE5OOUtWSjM0bVktakFmM3lYZTJzRTh0MkZrVFF6b0pqcktxd1ZkRFZTQW1aMDJoMUtRWS1MN2p5T0xrQXJUbGozWGxaZzBjV2x5RVZSZnc0djZna0RQeFNrN1oyeWlwVHo5c28wUTdScVBEUzltS1lpUjNfcEpGbGx2Sm1Xdklyb1owQTg3dHBYU2tR?oc=5", "source_name": "Market source", "published_at": "2026-07-05T07:00:00+00:00", "published_display": "05 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics Inc.(NasdaqCM:CNTX) added to Russell Microcap Growth Benchmark Index", "summary": "Context Therapeutics Inc. (NasdaqCM:CNTX) has been added to the Russell Microcap Growth Benchmark Index. This inclusion is part of several recent additions to various Russell indices, highlighting increased visibility for the biopharmaceutical company. Context Therapeutics focuse", "url": "https://www.marketscreener.com/news/context-therapeutics-inc-nasdaqcm-cntx-added-to-russell-microcap-growth-benchmark-index-ce7f5fded088f621", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T12:41:40", "published_display": "29 Jun 2026 12:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics Inc.(NasdaqCM: CNTX) added to Russell 3000E Growth Benchmark", "summary": "Context Therapeutics Inc. (NasdaqCM: CNTX) has been included in the Russell 3000E Growth Benchmark. This addition reflects the company's growth trajectory within the biotechnology and medical research sector. The article also provides a company profile, recent news, and various f", "url": "https://www.marketscreener.com/news/context-therapeutics-inc-nasdaqcm-cntx-added-to-russell-3000e-growth-benchmark-ce7f5fdedf88f320", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T08:40:20", "published_display": "29 Jun 2026 08:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Context Therapeutics, Inc. \u2013 MUN:6K9", "summary": "The article presents the \"Enterprise value to EBITDA forward\" metric for Context Therapeutics, Inc. (MUN:6K9) on the Munich Stock Exchange. It indicates that the market was closed with no trades recorded at the time of publication. The data is provided by FactSet Research Systems", "url": "https://www.tradingview.com/symbols/MUN-6K9/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T01:40:20", "published_display": "29 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Context Therapeutics Inc. \u2013 NASDAQ:CNTX", "summary": "This article provides financial data for Context Therapeutics Inc. (NASDAQ: CNTX), specifically focusing on its forward price-to-earnings ratio. It indicates that the company's financial information is available through TradingView, utilizing market data from ICE Data Services an", "url": "https://www.tradingview.com/symbols/NASDAQ-CNTX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T14:10:46", "published_display": "28 Jun 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Context Therapeutics Inc. \u2013 NASDAQ:CNTX", "summary": "This article provides financial data for Context Therapeutics Inc. (NASDAQ: CNTX), specifically focusing on its Price to Book Forward value. The content is presented within the TradingView platform, offering various financial tools and market data services.", "url": "https://www.tradingview.com/symbols/NASDAQ-CNTX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T20:10:21", "published_display": "27 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics (NASDAQ: CNTX) wins approval to lift share authorization to 300M", "summary": "Context Therapeutics (NASDAQ: CNTX) announced that its stockholders approved an amendment to increase the authorized common shares from 200 million to 300 million at their annual meeting on June 24, 2026. This decision provides the company with greater flexibility for future equi", "url": "https://www.stocktitan.net/sec-filings/CNTX/8-k-context-therapeutics-inc-reports-material-event-0e78f63100b2.html", "source_name": "Stock Titan", "published_at": "2026-06-26T21:09:42", "published_display": "26 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Context Therapeutics (CNTX) receives 45,000 stock options award", "summary": "Context Therapeutics Inc. (CNTX) director Karen L. Smith was granted 45,000 stock options with an exercise price of $0.576 per share, expiring on June 23, 2036. The options will vest on the earlier of June 24, 2027, or the company\u2019s 2027 annual meeting, contingent on her continue", "url": "https://www.stocktitan.net/sec-filings/CNTX/form-4-context-therapeutics-inc-insider-trading-activity-a47ea5ef3244.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:11:10", "published_display": "26 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics (CNTX) director awarded 45,000 stock options at $0.576", "summary": "Context Therapeutics Inc. director Stacey Jennifer Evans was granted 45,000 stock options at an exercise price of $0.576 per share. This compensation-related grant will vest on the earlier of June 24, 2027, or the company\u2019s 2027 annual meeting, contingent on her continued service", "url": "https://www.stocktitan.net/sec-filings/CNTX/form-4-context-therapeutics-inc-insider-trading-activity-46bdb4d41fda.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:11:10", "published_display": "26 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics (CNTX) director Linda West awarded 45K stock options", "summary": "Context Therapeutics director Linda West was granted 45,000 stock options to acquire common stock at an exercise price of $0.576 per share, expiring on June 23, 2036. The options will vest on the earlier of June 24, 2027, or the company\u2019s 2027 annual meeting, contingent on her co", "url": "https://www.stocktitan.net/sec-filings/CNTX/form-4-context-therapeutics-inc-insider-trading-activity-fd607db4f2e9.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:11:10", "published_display": "26 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics (CNTX) director receives grant of 45,000 stock options at $0.576", "summary": "Context Therapeutics Inc. director Andy Pasternak was granted 45,000 stock options with an exercise price of $0.576 per share, expiring on June 23, 2036. The options will vest on the earlier of June 24, 2027, or the company's 2027 annual meeting, dependent on his continued servic", "url": "https://www.stocktitan.net/sec-filings/CNTX/form-4-context-therapeutics-inc-insider-trading-activity-3a32fab9a01b.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:11:10", "published_display": "26 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics, Inc. Actuals & Estimates (NASDAQ:CNTX)", "summary": "This article provides an in-depth financial overview of Context Therapeutics Inc. (NASDAQ: CNTX), including its current stock price, historical performance, analyst forecasts, and key financial metrics like market capitalization and upcoming earnings reports. It also answers freq", "url": "https://www.tradingview.com/symbols/NASDAQ-CNTX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T07:10:15", "published_display": "26 Jun 2026 07:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics Highlights Positive CTIM-76 Phase 1 Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxOTk1lbFZidUx4bVVkYmdMZm1qMEtwb21pYVRhVV9VcE12eUNJZG5abjlYSGhyMGN1LWk1RVFKLS1JMXFqNnR5NHdLbkhBY0xoNHJoaFlzWWtzdTIwYmhJNVQ2VDhZcWs4Smc0amJxTlplRFFPVlp3YWxsLWIzWGhNMDNIQnJJMDV1WnlFZm1pNkc2OHNDVW9qMzJlaEJ5ZW05S0R3SXpVaWFiTFNVZWlkS1BKR19hRmVCdUhJNmZoMzJ0aFVoTFJsVlpEN3V1VHA5bnVxS2NWc1pEV3FrT0g4?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Study", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/small-biotech-context-therapeutics-reports-151023916.html", "source_name": "Benzinga", "published_at": "2026-06-15T15:10:23+00:00", "published_display": "15 Jun 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics to Proceed With Next Development Phase of CTIM-76 in Ovarian Cancer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/context-therapeutics-proceed-next-development-111656279.html", "source_name": "MT Newswires", "published_at": "2026-06-15T11:16:56+00:00", "published_display": "15 Jun 2026 11:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/context-therapeutics-announces-positive-interim-103000152.html", "source_name": "GlobeNewswire", "published_at": "2026-06-15T10:30:00+00:00", "published_display": "15 Jun 2026 10:30", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics Announces Positive Interim Efficacy", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAJBVV95cUxPalBnUWowcERlc1hFR2xKQ1NJc1RhN1VxMXBLa1plUVVpYzBEejVXZ3FTWmNEMWh4a1VkTHphaVhobE9UdnpnSWVfMV9VM2Q4N1IxaGZwZVVHSGZLTmJyMTdqbTl2cUltQUJWNEFTTW4zY3dCcmgzZWFnSF9xLWFreHMzd05PX3pEUDQxRUNvd3Y1LVdNdHVvTDBsdGVmQW9NSjRmNkp4akFrNGNmV2RKbTFYd0hta2pZYWVzZnVpb2pQYUQ2am5GV29TUzVwWlc0T0pfVER5d2NEaDRhVVY2czZiVTNrOGU0ejZ4a2lFSnlHMjQzdUlLclNwYU12QVE5bFJWSTNfV2x4WGdpdTdfUnJucVFqamozamlTSnptTjc?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics (NASDAQ: CNTX) shows early CTIM-76 activity in platinum-resistant ovarian cancer", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPejhseEJQdjZLbkRheWxOTHp3b3c3TDB5OXUzUDljN1g2VnZDdDU5ellYUTdOU3JyUDM5b0ExZ0N3OXlWdDVaTXQyLUIxZDJYNnJnaDAweHJ3b3FoTWFOSXBlbmE1M3ZXcFppS3puR0dwTVFtd1J3QjBRT05QbEVHdUZ4aDR4UTRFZEszaldBN0hfaVJBUlRnNktvTVpGS0FKT0lXRkFkVE1QY0N6cFk1QmhVNA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics to Present at the Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/context-therapeutics-present-jefferies-global-113000392.html", "source_name": "GlobeNewswire", "published_at": "2026-05-27T11:30:00+00:00", "published_display": "27 May 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics Decline Means Insider Profits Down To US$237k", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics Secures Full Rights to CT-202 Under Revised BioAtla Deal", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/context-therapeutics-secures-full-rights-112945130.html", "source_name": "MT Newswires", "published_at": "2026-05-18T11:29:45+00:00", "published_display": "18 May 2026 11:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Positive Signs As Multiple Insiders Buy Context Therapeutics Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQTmlUcjlidjRLZk5KeXEzNmNQNktrLVZPQUlQa2ZJUWpsUDhmZGNXZ0d4elVKX1BfSU9hN0lHbVliLXhrdmNLQlpzV1o5VVQyRVpEZDc3REgyQ184WUpjVGxKQkZtUjZ1X19uRzVXWmRsNGp1RVVILXJKMmNPZnNucV9mNy16VWd3bV80VHlwNUc1LVM4dHdnMW03RW5JbnFJdlBF?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Not Too Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTFB4a3IxaEZYQTVoc3pYbFlNV2gyd19tMU40QXhsSGl3cHhWVnZ6bWlrQlFWcjFyN1VJZW1YWndqd1loYlo5X3BpUXl0OTcwWEVSRDhoQjBwNlBpYl82bE1CXzR6UTVHWWFaNkdPUS1RVC01UG9iTkhB?oc=5", "source_name": "Market source", "published_at": "2026-02-05T08:00:00+00:00", "published_display": "05 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Hopeful That Context Therapeutics (NASDAQ:CNTX) Will Use Its Cash Wisely", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-19T08:00:00+00:00", "published_display": "19 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics (CNTX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5jNFdtMlFGaXhLcURsZmNsU3NfWlEwX2VfUnN5aFg3X2JKb3c5OHJmcEdHYm5GNzlubXpPV0hHdVM5eE1IRHY3Y3d0TG5JVW5NcFg0djNTbTItUQ?oc=5", "source_name": "MarketBeat", "published_at": "2021-10-25T23:22:47+00:00", "published_display": "25 Oct 2021 23:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics Completes $25M IPO", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPTVlpa1k4Qy16OXVuWEVNMzc1ckkxOUo5dzNJNmJtQUVIeDBvWVJtaTRYSmktVlJyeVAxVVlUZUQwM1JtQ0swUUxJcm5ubE9CWnI3NGE0SzVxVUF1UUlhZGtZaUY2ZmJZczdKQmczM0NQWjZJOHpOOFBLbHUweUZ4MFdiUkNKNUFPbGtQRGZaUjAtZXdycG5wOE1PLUpSMkdRbkE?oc=5", "source_name": "Faegre Drinker Biddle & Reath LLP", "published_at": "2021-10-19T07:00:00+00:00", "published_display": "19 Oct 2021 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxQSW9mM3I5d1lnaHgzVDlPNFgzSVg3MFNNVmk0N0hLcGh3dko0MF9kWUVzS1phTmdDU1NjUGFZamZZWTBmdnFfanllME9NWmhxd0JiMjJzM3JCQU9SVnY0cEx3T3JnT1pDUlh3Vy0xR1lDem9hZ2ZqdUFXd2UzU1JRbkczUEdHZ1hSRGdTN1JfSHgtLUxQVTBJRjNGbS15Z05pZVd0a25wZl9OX0VjNnp4WHVVOUxxeUVwbTJ1TmdMTzZvcEZVbTkzSDdEUFhvZTdtZC1fb3R2SFZ4ZzQ?oc=5", "source_name": "StockStory", "published_at": "2026-07-15T07:00:00+00:00", "published_display": "15 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 86, "total_relevant": 49, "sentiment_summary": {"positive": 16, "negative": 2, "neutral": 31, "score": 57, "total": 49, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 17.05, "count": 31}, {"event": "earnings", "label": "Earnings", "weight": 6.6, "count": 14}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 16, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 0.65, "latest_week": "2026-07-10", "one_week_move": -0.1, "four_week_move": -53.0, "twelve_week_move": -73.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.064508, "market_dynamics_buy_signal": false, "relative_strength": -64.572238, "fair_value_gap": -53.6, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 45.4974, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.1% over one week, -53.0% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 57, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 8}, {"label": "Market source", "count": 8}, {"label": "Stock Titan", "count": 8}, {"label": "GlobeNewswire", "count": 5}, {"label": "simplywall.st", "count": 4}, {"label": "www.marketscreener.com", "count": 3}, {"label": "Quartr", "count": 2}, {"label": "MT Newswires", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 41}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 31}, {"label": "Earnings", "count": 14}, {"label": "Balance sheet", "count": 2}, {"label": "Regulatory and legal", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "41", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-0.1% over one week, -53.0% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Enterprise value to revenue forward of Context Therapeutics, Inc. \u2013 DUS:6K9"}], "updated_at": "2026-07-16T18:58:22.190908+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}